about
Impaired endocytosis of the ion channel TRPM4 is associated with human progressive familial heart block type ICalsequestrin mutations and catecholaminergic polymorphic ventricular tachycardiaGenetics of sudden cardiac death syndromesAnimal models of autism spectrum disorders: information for neurotoxicologistsGenome-wide association of implantable cardioverter-defibrillator activation with life-threatening arrhythmiasMyofilament Ca2+ sensitization causes susceptibility to cardiac arrhythmia in mice.Synchronization of chaotic early afterdepolarizations in the genesis of cardiac arrhythmias.Flecainide inhibits arrhythmogenic Ca2+ waves by open state block of ryanodine receptor Ca2+ release channels and reduction of Ca2+ spark mass.Role of the cytoplasmic N-terminal Cap and Per-Arnt-Sim (PAS) domain in trafficking and stabilization of Kv11.1 channels.HRS policy statement: clinical cardiac electrophysiology fellowship curriculum: update 2011Potential role of cardiac calsequestrin in the lethal arrhythmic effects of cocainePitx2 prevents susceptibility to atrial arrhythmias by inhibiting left-sided pacemaker specificationConnexin mutant embryonic stem cells and human diseasesGenetic variation in the rhythmonome: ethnic variation and haplotype structure in candidate genes for arrhythmias.Enhanced cardiac function in Gravin mutant mice involves alterations in the β-adrenergic receptor signaling cascadeTriadin regulates cardiac muscle couplon structure and microdomain Ca(2+) signalling: a path towards ventricular arrhythmias.Amitriptyline activates cardiac ryanodine channels and causes spontaneous sarcoplasmic reticulum calcium releaseACE I/D polymorphism associated with abnormal atrial and atrioventricular conduction in lone atrial fibrillation and structural heart disease: implications for electrical remodeling.Discrete effects of A57G-myosin essential light chain mutation associated with familial hypertrophic cardiomyopathyMolecular mechanisms of inherited arrhythmias.Postischemic cardiac recovery in heme oxygenase-1 transgenic ischemic/reperfused mouse myocardium.Induced pluripotent stem cell-derived cardiomyocytes: boutique science or valuable arrhythmia model?Pathophysiology, prevention, and treatment of commotio cordis.Cardiovascular risks and benefits of moderate and heavy alcohol consumption.Quantifying the origins of population variability in cardiac electrical activity through sensitivity analysis of the electrocardiogram.The importance of being profiled: improving drug candidate safety and efficacy using ion channel profiling.Power and pitfalls of using transgenic mice to optimize therapy for CPVT: a need for prospective placebo-controlled clinical trials in genetic arrhythmia disorders.Voltage-gated calcium channel CACNB2 (β2.1) protein is required in the heart for control of cell proliferation and heart tube integrity.Azithromycin Causes a Novel Proarrhythmic Syndrome.Trafficking defects in PAS domain mutant Kv11.1 channels: roles of reduced domain stability and altered domain-domain interactions.
P2860
Q24312557-D08037A0-EC5A-4FD4-B2CD-A4F6648BFB85Q28262015-1BA179C2-A348-4B57-BC52-A2E4438DDF5EQ28307856-47BD7F6A-5903-4228-A2EE-AA8971224A02Q28385566-A744CCF6-9E59-40DD-BF2B-422680C2D9C6Q28732889-E8AFBD31-2296-4A35-A9F7-9178C6C3C79DQ30484558-099123A9-EC11-4A78-9820-C1241A3E7D96Q30486315-2588ECF1-7049-4B99-AC6E-44C485BCCBDAQ33618629-F33622A0-72BA-41B9-BA39-8D460E090C1FQ33619341-02628CA9-9F57-432C-B1F6-301DB5BABD37Q33815633-C425AF55-5FB9-4F7B-9C8C-8816441F1233Q33899158-70595063-642C-4278-9C40-986A183CF2ADQ34006337-B399E30D-F3D9-495B-8C37-C5A2CB25B258Q34259105-D982D21E-B0DD-40C8-AE12-CCA966CB349AQ34987142-03DA3FE5-4A04-4CE5-BF97-B13F1A89B961Q34994899-A2DB824E-483D-48E3-9E3F-9E5EF571A867Q36786528-58FAEA31-5F11-492A-9B5F-9C155472F4C4Q37199462-2A52F09D-AF55-42DD-91DA-4B41FB72FD8CQ37339741-2B1EB3EC-13B3-4AF2-8972-5213FCDFE74CQ37476496-16B39518-34A8-4D5D-AEAA-5789C8CA4BBCQ37480777-8D8545E6-E515-4D09-9FF3-17CD1B9176E3Q37568669-297D9DAC-12B4-4BCF-BC6D-23EBFDC92968Q38097414-10FFB549-4514-44EE-BA49-4D86E47CEDE0Q38206725-39F047E8-7318-4B1A-BAFB-35A2CC418C23Q38534581-0B4400E6-A16D-461E-8ED2-3E90E83A435DQ39440862-2518324A-1392-4384-9463-7323FD410664Q39749838-9B678D51-005E-4BDE-B47E-65FDE5E23D60Q41988117-FAE0F99D-4ED5-4FAA-A129-C18F3E4CBC16Q47073802-29DCE1B6-F2F1-473E-953B-5EB392B84C15Q50728603-D232CA34-6295-4425-B928-A28B110C304BQ50950249-91D145A5-E3C0-499E-A9A1-3D44073938E2
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A genetic framework for improving arrhythmia therapy.
@en
A genetic framework for improving arrhythmia therapy.
@nl
type
label
A genetic framework for improving arrhythmia therapy.
@en
A genetic framework for improving arrhythmia therapy.
@nl
prefLabel
A genetic framework for improving arrhythmia therapy.
@en
A genetic framework for improving arrhythmia therapy.
@nl
P2860
P356
P1433
P1476
A genetic framework for improving arrhythmia therapy
@en
P2093
Dan M Roden
P2860
P2888
P304
P356
10.1038/NATURE06799
P407
P577
2008-02-01T00:00:00Z